Literature DB >> 9029023

Idiotype-specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets.

Q Yi1, I Eriksson, W He, G Holm, H Mellstedt, A Osterborg.   

Abstract

Tumour-specific CD4+ T helper (Th) and CD8+ T cytotoxic (Tc) cells may participate in the control and eradication of tumour cells. In the present study, idiotype-specific stimulation of CD4+ and CD8+ blood T cells from patients with monoclonal gammopathy of undetermined significance and patients with untreated multiple myeloma stage I was examined. Activation was measured in the CD4+ and CD8+ subsets enriched by magnetic microbeads as the incorporation of 3H-thymidine and the secretion of interferon (IFN)-gamma, interleukin (IL)-2 and IL-4 by single cells using the enzyme-linked immunospot assay. Idiotype-specific T cells were found in four of seven patients. Stimulation was mainly confined to the CD4+ subset in three of the four responding patients. This type of response was major histocompatibility complex (MHC) class II restricted as it could be inhibited by monoclonal antibodies against MHC class II (HLA-DR), but not against class I (HLA-ABC) molecules. Idiotype-specific CD8+ T cells were also demonstrated in these patients although at a lower frequency. One patient showed a strong and dominating activation of CD8+ T cells which could be blocked by antibodies against HLA-ABC but not against HLA-DR. Idiotype-specific CD4+ or CD8+ T cells were mainly of the type-1 subsets as judged by their secretion of IFN-gamma and IL-2. Thus, this study provides evidence for the presence of idiotype-specific and MHC-restricted CD4+ and CD8+ T cells of the type-1 subsets in patients with monoclonal gammopathies. Such T cells with the potential to control the growth of tumour B cells may be a suitable target for immunotherapeutic interventions in patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029023     DOI: 10.1046/j.1365-2141.1997.d01-2021.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.

Authors:  Siqing Wang; Sungyoul Hong; Jing Yang; Jianfei Qian; Xiang Zhang; Elizabeth Shpall; Larry W Kwak; Qing Yi
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

2.  MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.

Authors:  Qiang Wang; Dongyu Zhao; Miao Xian; Zhuo Wang; Enguang Bi; Pan Su; Jianfei Qian; Xingzhe Ma; Maojie Yang; Lintao Liu; Youli Zu; Sai Ravi Pingali; Kaifu Chen; Zhen Cai; Qing Yi
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

Review 3.  Novel immunotherapies.

Authors:  Qing Yi
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

4.  Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.

Authors:  Sungyoul Hong; Jianfei Qian; Jing Yang; Haiyan Li; Larry W Kwak; Qing Yi
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

5.  Multiple myeloma: VI International Workshop, June 14-18, 1997, Boston, Massachusetts, USA.

Authors:  S Bergenbrant
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

Review 6.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10

7.  CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability.

Authors:  Xingzhe Ma; Liuling Xiao; Lintao Liu; Lingqun Ye; Pan Su; Enguang Bi; Qiang Wang; Maojie Yang; Jianfei Qian; Qing Yi
Journal:  Cell Metab       Date:  2021-03-09       Impact factor: 27.287

8.  Lymphomas can develop from B cells chronically helped by idiotype-specific T cells.

Authors:  Michael M Zangani; Marianne Frøyland; Gao Yue Qiu; Leonardo A Meza-Zepeda; Jeffery L Kutok; Keith M Thompson; Ludvig A Munthe; Bjarne Bogen
Journal:  J Exp Med       Date:  2007-05-07       Impact factor: 14.307

9.  Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Keren Osman; Matthew D Geller
Journal:  J Exp Med       Date:  2003-11-24       Impact factor: 14.307

10.  Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.

Authors:  Lintao Liu; Enguang Bi; Xingzhe Ma; Wei Xiong; Jianfei Qian; Lingqun Ye; Pan Su; Qiang Wang; Liuling Xiao; Maojie Yang; Yong Lu; Qing Yi
Journal:  Nat Commun       Date:  2020-11-19       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.